Table 1 Patient Demographics and Baseline Characteristics
| Â | IFX | GLM |
|---|---|---|
Number of Patients | 389 | 421 |
Male Gender, n (%) | 244 (62.7%) | 249 (59.1%) |
Mean (SD) Age, years | 45.6 (11.9) | 45.7 (13.3) |
Mean (SD) Weight, Kg | 79.8 (18.4) | 81.9 (18.3) |
Disease Duration | ||
 Mean (SD) | 8.6 (9.8) | 6.0 (10.1) |
 Median | 4.0 | 1.6 |
HLA B27, n/N (%) | 27/42 (64.2%) | 47/62 (75.8%) |
Uveitis, n/N (%) | ||
 History | 19/67 (28.3%) | 53/369 (14.3%) |
 If yes, present? | 3/19 (15.7%) | 4/46 (8.7%) |
Psoriasis, n (%) | ||
 History | 8/66 (12.1%) | 58/376 (15.4%) |
 If yes, present? | 6/8 (75.0%) | 40/56 (71.4%) |
Inflammatory Bowel Disease, n (%) | ||
 History | 11/67 (16.4%) | 33/373 (8.8%) |
 If yes, present? | 8/9 (88.9%) | 21/32 (65.6%) |
Peripheral Arthritis, n (%) | ||
 History | 20/67 (30.0%) | 143/373 (38.3%) |
 If yes, present? | 13/18 (72.2%) | 115/137 (83.9%) |
Presence of Enthesitis (n/N, %) | 21/360 (5.5%) | 135/340 (39.7%) |
Presence of dactylitis (n/N, %) | 8/241 (3.3%) | 31/235 (13.2%) |
Previous Therapies (n, %) | ||
 NSAIDs | 302, 77.6% | 343, 81.5% |
 Corticosteroids | 97, 24.9% | 97, 23.0% |
 DMARDs | 99, 25.4% | 61, 22.8% |
Concomitant Therapies (n, %) | ||
 NSAIDs | 251, 64.5% | 281, 66.8% |
 Corticosteroids | 44, 11.3% | 51/421, 12.1% |
 MTX | 79, 20.3% | 41/421 (9.7%) |
Bio-naive, % | 91.3% | 82.7% |
BASDAI | ||
 Available n | 374 | 405 |
 Median | 6.5 | 6.5 |
 Mean (SD, 95% C.I) | 6.3 (2.2, 6.1–6.5) | 6.1 (2.1, 5.9–6.3) |
BASFI | ||
 Available n | 374 | 403 |
 Median | 6.3 | 5.6 |
 Mean (SD, 95% C.I) | 5.9 (2.5, 5.7–6.2) | 5.3 (2.4, 5.1–5.6) |
PtGA | ||
 Available n | 96 | 256 |
 Median | 64 | 70 |
 Mean (SD, 95% C.I) | 59.4 (27.8, 53.8–65.1) | 61.6 (24.6, 58.5–64.6) |
MDGA | ||
 Available n | 385 | 414 |
 Median | 7.0 | 6.0 |
 Mean (SD, 95% C.I) | 6.3 (2.1, 6.1–6.5) | 5.5 (2.1, 5.3–6.0) |
HAQ | ||
 Available n | 376 | 399 |
 Median | 1.1 | 1.0 |
 Mean (SD, 95% C.I) | 1.2 (0.6, 1.1–1.2) | 1.0 (0.6, 1.0–1.1) |
CRP (mg/ml) | ||
 Available n | 312 | 319 |
 Median | 9.0 | 5.9 |
 Mean (SD, 95% C.I) | 18.0 (27.8, 14.9–21.1) | 14.8 (30.9, 11.4–18.2) |
ESR (mm/hr) | ||
 Available n | 333 | 308 |
 Median | 18.0 | 12.0 |
 Mean (SD, 95% C.I) | 23.5 (20.7, 21.3–25.8) | 17.2 (15.5, 15.4–18.9) |
ASDAS | ||
 Mean (SD, 95% C.I)) | 3.7 (1.1, 3.6–3.8) | 3.4 (1.0, 3.3–3.5) |
 Median | 3.8 | 3.4 |
 Inactive (% < 1.3) | 2.4% | 2.7% |
 Moderate (% 1.3–2.0) | 3.9% | 7.5% |
 High (% 2.1–3.5) | 35.5% | 48.1% |
 Very High (% > 3.5) | 58.3% | 38.3% |